23andMe Makes Changes to API Policy for Third-Party App Developers

Aug 24, 2018

|

NEW YORK (GenomeWeb) – Consumer genomics company 23andMe let customers know this week that it will restrict its application programming interface (API) to select third-party apps.

The firm said that in two weeks it would disable other apps' ability to access customers' 23andMe results through its API. In effect, customers that have shared their 23andMe reports with other apps through its API may no longer work.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Earlier in the US

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

How the Proteins Shape Up

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

Who's to Be First?

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

PNAS Papers on Ovarian Cancer, Retrotransposon Insertions in Cancer, Malaria Mosquitoes

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.

Menu

23andMe Makes Changes to API Policy for Third-Party App Developers

To read the full story....

Breaking News

Veracyte, Twist Bioscience Lead November GenomeWeb Index on Strong Earnings Growth

Thermo Fisher Scientific Raises Q4 and 2020 Revenue, Earnings Guidance

Newomics Closes $7.9M Series B Funding Round

UnitedHealthcare to Cover NIPT for Average-Risk Pregnancies

Illumina, PierianDx Expand Partnership on Cancer Panel Test Reporting

Canadian Consortium Launches COVID Cloud to Support Molecular Research

The Scan

Earlier in the US

How the Proteins Shape Up

Who's to Be First?

PNAS Papers on Ovarian Cancer, Retrotransposon Insertions in Cancer, Malaria Mosquitoes

What's Popular?

Grail Inks Deal With UK National Health Service to Offer Cancer Screening Blood Test in 2021

Progenity to Raise $100M in Separate Public Stock, Private Senior Notes Offerings

AquaVitas Partners With HHS, CDC on Wastewater Coronavirus Study

Startup Angstrom Bio Plans Saliva-Based COVID-19 Nucleic Acid Test on Nanopore Sequencing Platform

Cepheid, Roche Coronavirus Tests Get FDA Emergency Use Authorization

Sponsorships